Article | Published:

Partial DNA-guided Cas9 enables genome editing with reduced off-target activity

Nature Chemical Biology volume 14, pages 311316 (2018) | Download Citation

This article has been updated


CRISPR–Cas9 is a versatile RNA-guided genome editing tool. Here we demonstrate that partial replacement of RNA nucleotides with DNA nucleotides in CRISPR RNA (crRNA) enables efficient gene editing in human cells. This strategy of partial DNA replacement retains on-target activity when used with both crRNA and sgRNA, as well as with multiple guide sequences. Partial DNA replacement also works for crRNA of Cpf1, another CRISPR system. We find that partial DNA replacement in the guide sequence significantly reduces off-target genome editing through focused analysis of off-target cleavage, measurement of mismatch tolerance and genome-wide profiling of off-target sites. Using the structure of the Cas9–sgRNA complex as a guide, the majority of the 3′ end of crRNA can be replaced with DNA nucleotide, and the 5 - and 3′-DNA-replaced crRNA enables efficient genome editing. Cas9 guided by a DNA–RNA chimera may provide a generalized strategy to reduce both the cost and the off-target genome editing in human cells.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Change history

  • 05 February 2018

    In the HTML version of this article initially published online, the received date was incorrectly stated as 18 May 2017. The date should be 5 October 2017. This error has been corrected in the HTML version of the article.


Primary accessions



  1. 1.

    et al. Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819–823 (2013).

  2. 2.

    et al. RNA-guided human genome engineering via Cas9. Science 339, 823–826 (2013).

  3. 3.

    & Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 346, 1258096 (2014).

  4. 4.

    et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337, 816–821 (2012).

  5. 5.

    , & Therapeutic genome editing: prospects and challenges. Nat. Med. 21, 121–131 (2015).

  6. 6.

    et al. DNA-guided DNA interference by a prokaryotic Argonaute. Nature 507, 258–261 (2014).

  7. 7.

    et al. Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage. Mol. Cell 19, 405–419 (2005).

  8. 8.

    et al. An unbiased genome-wide analysis of zinc-finger nuclease specificity. Nat. Biotechnol. 29, 816–823 (2011).

  9. 9.

    et al. In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites. Nucleic Acids Res. 41, e181 (2013).

  10. 10.

    et al. GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat. Biotechnol. 33, 187–197 (2015).

  11. 11.

    et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat. Biotechnol. 33, 179–186 (2015).

  12. 12.

    et al. Digenome-seq: genome-wide profiling of CRISPR–Cas9 off-target effects in human cells. Nat. Methods 12, 237–243 (2015).

  13. 13.

    et al. Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. Nat. Biotechnol. 33, 175–178 (2015).

  14. 14.

    et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 154, 1380–1389 (2013).

  15. 15.

    et al. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat. Biotechnol. 31, 833–838 (2013).

  16. 16.

    et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing. Nat. Biotechnol. 32, 569–576 (2014).

  17. 17.

    , & Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification. Nat. Biotechnol. 32, 577–582 (2014).

  18. 18.

    et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84–88 (2016).

  19. 19.

    et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495 (2016).

  20. 20.

    et al. DNA-binding-domain fusions enhance the targeting range and precision of Cas9. Nat. Methods 12, 1150–1156 (2015).

  21. 21.

    , , , & Improving CRISPR-Cas nuclease specificity using truncated guide RNAs. Nat. Biotechnol. 32, 279–284 (2014).

  22. 22.

    et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat. Biotechnol. 33, 985–989 (2015).

  23. 23.

    et al. Synthetic CRISPR RNA-Cas9-guided genome editing in human cells. Proc. Natl. Acad. Sci. USA 112, E7110–E7117 (2015).

  24. 24.

    et al. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).

  25. 25.

    , , , & A Cas9-guide RNA complex preorganized for target DNA recognition. Science 348, 1477–1481 (2015).

  26. 26.

    et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014).

  27. 27.

    et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell 154, 442–451 (2013).

  28. 28.

    , , & Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).

  29. 29.

    et al. DNA targeting specificity of RNA-guided Cas9 nucleases. Nat. Biotechnol. 31, 827–832 (2013).

  30. 30.

    et al. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat. Biotechnol. 32, 551–553 (2014).

  31. 31.

    et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 163, 759–771 (2015).

  32. 32.

    & Relative thermodynamic stability of DNA, RNA, and DNA:RNA hybrid duplexes: relationship with base composition and structure. Biochemistry 34, 10807–10815 (1995).

  33. 33.

    , , & The orientation and dynamics of the C2′-OH and hydration of RNA and DNA.RNA hybrids. Nucleic Acids Res. 26, 3104–3110 (1998).

  34. 34.

    et al. Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing. Nat. Biotechnol. 35, 1179–1187 (2017).

  35. 35.

    et al. Therapeutic genome editing by combined viral and non-viral delivery of CRISPR system components in vivo. Nat. Biotechnol. 34, 328–333 (2016).

  36. 36.

    et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 520, 186–191 (2015).

  37. 37.

    et al. Efficient genome engineering in human pluripotent stem cells using Cas9 from Neisseria meningitidis. Proc. Natl. Acad. Sci. USA 110, 15644–15649 (2013).

  38. 38.

    et al. Synthetically modified guide RNA and donor DNA are a versatile platform for CRISPR-Cas9 engineering. eLife 6, e25312 (2017).

  39. 39.

    & Designing chemically modified oligonucleotides for targeted gene silencing. Chem. Biol. 19, 937–954 (2012).

  40. 40.

    et al. Controlling miRNA-like off-target effects of an siRNA with nucleobase modifications. Org. Biomol. Chem. 15, 10029–10036 (2017).

  41. 41.

    et al. Position-specific chemical modification of siRNAs reduces “off-target” transcript silencing. RNA 12, 1197–1205 (2006).

  42. 42.

    et al. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy. Nature 550, 407–410 (2017).

  43. 43.

    et al. Cas9 gRNA engineering for genome editing, activation and repression. Nat. Methods 12, 1051–1054 (2015).

  44. 44.

    et al. Orthogonal gene knockout and activation with a catalytically active Cas9 nuclease. Nat. Biotechnol. 33, 1159–1161 (2015).

  45. 45.

    , , , & Conjugation and evaluation of triazole-linked single guide RNA for CRISPR-Cas9 gene editing. ChemBioChem 17, 1809–1812 (2016).

  46. 46.

    et al. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5, 97–110 (2009).

  47. 47.

    , & Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).

  48. 48.

    et al. GUIDEseq: a bioconductor package to analyze GUIDE-seq datasets for CRISPR-Cas nucleases. BMC Genomics 18, 379 (2017).

Download references


We thank T. Jacks, P. Sharp, Z. Weng, C. Mello, and E. Sontheimer for discussions, and Y. Li for technical assistance. We thank K. Joung (Massachusetts General Hospital and Harvard Medical School) for sharing U2OS-GFP-PEST cells and J. Smith and A. Sheel for proofreading. This work is supported by grants from the National Institutes of Health (NIH), 5R00CA169512, DP2HL137167 and P01HL131471 (to W.X.). H.Y. is supported by 5-U54-CA151884-04 (NIH) and Skoltech Center. W.X. was supported by the Lung Cancer Research Foundation, Hyundai Hope on Wheels, and ALS Association. This work is supported in part by Cancer Center Support (core) grant P30-CA14051 from the NIH. We thank the Swanson Biotechnology Center at MIT for technical support.

Author information

Author notes

    • Hao Yin
    •  & Chun-Qing Song

    These authors contributed equally to this work.


  1. David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Hao Yin
    • , Sneha Suresh
    • , Qiongqiong Wu
    • , Stephen Walsh
    • , Junmei Ding
    • , Roman L Bogorad
    • , Robert Langer
    •  & Daniel G Anderson
  2. RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

    • Chun-Qing Song
    • , Suet-Yan Kwan
    •  & Wen Xue
  3. Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

    • Lihua Julie Zhu
    • , Scot A Wolfe
    •  & Wen Xue
  4. Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

    • Lihua Julie Zhu
  5. Department of Molecular Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

    • Lihua Julie Zhu
    •  & Wen Xue
  6. Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, Massachusetts, USA.

    • Scot A Wolfe
  7. Skolkovo Institute of Science and Technology, Skolkovo, Moscow Region, Russia.

    • Victor Koteliansky
  8. Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Robert Langer
    •  & Daniel G Anderson
  9. Harvard-MIT Division of Health Sciences and Technology, Cambridge, Massachusetts, USA.

    • Robert Langer
    •  & Daniel G Anderson
  10. Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Robert Langer
    •  & Daniel G Anderson


  1. Search for Hao Yin in:

  2. Search for Chun-Qing Song in:

  3. Search for Sneha Suresh in:

  4. Search for Suet-Yan Kwan in:

  5. Search for Qiongqiong Wu in:

  6. Search for Stephen Walsh in:

  7. Search for Junmei Ding in:

  8. Search for Roman L Bogorad in:

  9. Search for Lihua Julie Zhu in:

  10. Search for Scot A Wolfe in:

  11. Search for Victor Koteliansky in:

  12. Search for Wen Xue in:

  13. Search for Robert Langer in:

  14. Search for Daniel G Anderson in:


H.Y. conceived of and designed the study and directed the project. H.Y., C.-Q.S, S.S., S.W., Q.W., J.D., S.-Y.K., L.J.Z., and S.A.W. performed experiments and analyzed data. H.Y. made the figures with C.-Q.S. V.K., W.X., and R.L.B., and R.L. provided conceptual advice. H.Y. wrote the manuscript with comments from all authors. W.X., D.G.A. and R.L. supervised the project.

Competing interests

H.Y., C.-Q.S., W.X., D.G.A and R.L. have applied for patents related to this study. D.G.A. is a scientific co-founder of CRISPR Therapeutics.

Corresponding authors

Correspondence to Wen Xue or Robert Langer or Daniel G Anderson.

Supplementary information

PDF files

  1. 1.

    Supplementary Text and Figures

    Supplementary Tables 1–2 and Supplementary Figures 1–6

  2. 2.

    Life Sciences Reporting Summary

Excel files

  1. 1.

    Supplementary Data Set 1

    Details of GUIDE-seq analysis of native and 10 DNA crRNAs of three endogenous genes

About this article

Publication history





Further reading